Primary Immune Thrombocytopenia (ITP)

Primary immune thrombocytopenia (ITP) is an acquired autoimmune disorder affecting both children and adults, characterised by a platelet count below 100 × 109/l. Clinical manifestations include petechiae, purpura, bruising, and overt bleeding. In most children, this condition remits spontaneously in 6 months and requires minimal medical treatment.
On contrary, the adult form of the disease is usually not prodrome.

Showing the single result

Filter our product list:
API
Antigen / Target
Therapeutic Areas
Therapeutic Indications
1
Classes of molecule​s
Isotypes
Expiry Date
CoA
Filters Sort results
Reset Apply

Product
Batch

Antigen
Molecular Class
Drug Brand
Product Concentration
CoA
Quantity per vial
Storage Temperature
Expiry Date
Price from
TPO receptor (cMpl)
Peptibody
,
Therapeutic peptides
Nplate®
0,5 mg/mL
0,02 mg
-80°C
05/2025
613,00 
view product
Max: 4
Min: 1
Step: 1

Not looking for Primary Immune Thrombocytopenia (ITP)?

Search our therapeutic molecules product database